Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affymax FY10 revenues down
The company’s loss from operations was $14.45m for the full year ended 31 December 2010, compared to $78.94m for the same period in 2009. Affymax has generated net
The company’s loss from operations was $14.45m for the full year ended 31 December 2010, compared to $78.94m for the same period in 2009. Affymax has generated net
The Phase II trials will evaluate the drug candidate in patients with post herpetic neuralgia (PHN) and overactive bladder. AGN-214868 was discovered under the partnership using Syntaxin’s proprietary
TRV120027 is a beta-arrestin biased angiotensin II type 1 receptor (AT1R) ligand, the first biased ligand designed to treat patients with AHF. The randomised, placebo-controlled, double-blind, dose-ranging Phase
Life Sciences organizations have to cut the cost, time and complexity of bringing safe and effective products to market and at the same time must also comply with
FOSAMAX is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Reportedly, the plaintiff in this case alleged she used FOSAMAX from 1999 to 2006 and
The randomised, double-blind, placebo-controlled Phase I Study evaluated the safety, tolerability and pharmacokinetic profile of NRM8499, compared to tramiprosate in 67 young and elderly healthy subjects. The study
Adva-27a is a small molecule inhibitor of Topoisomerase II, an enzyme found in abundance in multi-drug resistant breast cancer as well as in other types of aggressive cancer.
In its CRL, the FDA has showed its concern regarding the use of the in-vitro performance data and clinical pharmacology data to bridge MannKind‘s next generation inhaler to
VistaGen said that the NIH grant will support further development of patient-specific iPS cell programming processes by NuPotential, as well as VistaGen’s differentiation protocols and processes focused on
Caliper Life Sciences president and CEO Kevin Hrusovsky said the deal will improve the economics of diagnostic testing and advance the worldwide implementation of personalised medicine. "We believe